Akela Pharma repeats its Fentanyl TAIFUN(R) preclinical toxicology studies www.akelapharma.com Toronto Stock Exchange Symbol: AKL MONTREAL (CNW) - Akela Pharma Inc.(TSX: 'AKL'), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that as previously...
Akela Pharma repeats its Fentanyl TAIFUN(R) preclinical toxicology studies AM Attention Business/Financial Editors www.akelapharma.com Toronto Stock Exchange Symbol: AKL MONTREAL, July 8 /CNW Telbec/ - Akela Pharma Inc.(TSX: 'AKL'), a drug development company focused on developing therapies for the inhalation...
Akela Pharma repeats its Fentanyl TAIFUN(R) preclinical toxicology studies AM Attention Business/Financial Editors www.akelapharma.com Toronto Stock Exchange Symbol: AKL MONTREAL, July 8 /CNW Telbec/ - Akela Pharma Inc.(TSX: 'AKL'), a drug development company focused on developing therapies for the inhalation...
Akela Pharma repeats its Fentanyl TAIFUN(R) preclinical toxicology studies www.akelapharma.com Toronto Stock Exchange Symbol: AKL MONTREAL, July 8 /CNW Telbec/ - Akela Pharma Inc.(TSX: 'AKL'), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that as...
Akela Pharma repeats its Fentanyl TAIFUN(R) preclinical toxicology studies www.akelapharma.com Toronto Stock Exchange Symbol: AKL MONTREAL, July 8 /CNW Telbec/ - Akela Pharma Inc.(TSX: 'AKL'), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that as...
Akela Pharma repeating Fentanyl inhalant safety study at FDA request MONTREAL - Akela Pharma Inc.(TSX:AKL) has started over again with safety studies on its Tamifun platform for inhaled drugs, as required by the U.S.
Food and Drug Administration.
Akela said Tuesday it remains on track to make...
Akela Pharma repeating Fentanyl inhalant safety study at FDA request MONTREAL - Akela Pharma Inc.(TSX:AKL) has started over again with safety studies on its Tamifun platform for inhaled drugs, as required by the U.S.
Food and Drug Administration.
Akela said Tuesday it remains on track to make...
Akela Pharma repeating Fentanyl inhalant safety study at FDA request MONTREAL - Akela Pharma Inc.(TSX:AKL) has started over again with safety studies on its Tamifun platform for inhaled drugs, as required by the U.S.
Food and Drug Administration.
Akela said Tuesday it remains on track to make...
Akela Pharma repeating Fentanyl inhalant safety study at FDA request MONTREAL - Akela Pharma Inc.(TSX:AKL) has started over again with safety studies on its Tamifun platform for inhaled drugs, as required by the U.S.
Food and Drug Administration.
Akela said Tuesday it remains on track to make...
Akela Pharma repeating Fentanyl inhalant safety study at FDA request MONTREAL - Akela Pharma Inc.(TSX: AKL.TO) has started over again with safety studies on its Tamifun platform for inhaled drugs, as required by the U.S.
Food and Drug Administration.
Akela said Tuesday it remains on track to make...
Akela Pharma repeating Fentanyl inhalant safe The studies are 'expected to produce results allowing Akela to start the longer term safety arm of the Fentanyl (cancer pain drug) Taifun Phase 3 clinical trial in patients in the second quarter of 2009,' the Montreal drug development...
Akela Pharma repeating Fentanyl inhalant safety study at FDA request The studies are 'expected to produce results allowing Akela to start the longer term safety arm of the Fentanyl (cancer pain drug) Taifun Phase 3 clinical trial in patients in the second quarter of 2009,' the Montreal drug development...
Akela Pharma repeating Fentanyl inhalant safety study at FDA request MONTREAL - Akela Pharma Inc.(TSX:AKL) has started over again with safety studies on its Tamifun platform for inhaled drugs, as required by the U.S.
Food and Drug Administration.
Akela said Tuesday it remains on track to make...
Akela Pharma repeating Fentanyl inhalant safety study at FDA request MONTREAL - Akela Pharma Inc.(TSX:AKL) has started over again with safety studies on its Tamifun platform for inhaled drugs, as required by the U.S.
Food and Drug Administration.
Akela said Tuesday it remains on track to make...
Akela Pharma repeats its Fentanyl Taifun preclinical toxicology studies Toronto MONTREAL 'We are still on track to deliver the required toxicology studies results in time to allow us to meet our previously disclosed regulatory submission timelines of Q1-2010 for the E.U.and Q3-2010 for the U.S.
About Akela...
Akela restarts preclinical toxicology studies for cancer pain drug Akela Pharma has announced that as previously requested by the FDA, it has started over again the required inhalation toxicology studies.The studies performed at US based CRO are expected to produce results allowing Akela to start the longer...
Akela Pharma repeating Fentanyl inhalant safety study at FDA request _ Akela Pharma repeating Fentanyl inhalant safety study at FDA request.
Akela Pharma Repeats its Fentanyl Taifun Preclinical Toxicology Studies _ Akela Pharma Repeats its Fentanyl Taifun Preclinical Toxicology Studies.
Akela Pharma restarts inhalation toxicology studies AKELA PHARMA REPEATS ITS FENTANYL TAIFUN(R) PRECLINICAL TOXICOLOGY STUDIES Akela Pharma Inc., as previously requested by the Food and Drug Administration, has started over again the required inhalation toxicology studies.Akela...
NPSA alert: Reducing Dosing Errors with Opioid Medicines In response to reports of five deaths and over 4,200 dose-related patient safety incidents concerning opioid medicines up to June 2008, the National Patient Safety Agency (NPSA) has issued a rapid response report designed to help reduce...
Ameritox, Ltd., Announces Addition of LC-MS/MS - the Industry's Most Advanced Analytical Method for Detecting , 9:30 AM EST News source: Business Wire Ameritox, Ltd., the U.S.leader in pain prescription urine drug monitoring, today announced its addition of the industry's most advanced, most sensitive analytical method for detecting prescription...
Glide Pharma announces third new pharma partner for 2008 at BIO, strengthening its biologics pipeline Oxford, UK, 17th June 2008 Specialty pharma company, Glide Pharma, today announced at BIO2008 that it has signed agreements with two more partners to evaluate the Glide SDI - Solid Dose Injector.This follows a deal in February with...
Intelence, Vimpat and Rapinyl get CHMP backing The European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has issued its latest list of opinions which has seen the agency back Johnson & Johnsons new HIV drug Intelence.The CHMP has recommended the...
Sublingual Fentanyl Approved in Europe for Breakthrough Cancer Pain Angiogenesis Inhibition in the Treatment of Solid Tumors: State of the Science Managing Adverse Effects in Patients With Lung Cancer Receiving Antiangiogenic Therapy Managing Adverse Effects in Patients With Colorectal Cancer Receiving...
Advisory Panel for European Regulatory Board Weighs In Positively on Three Drugs The European regulatory advisory committee is backing the approval of ProStrakans cancer pain drug, Tibotecs HIV therapy, and a medication for generalized anxiety disorder (GAD) from Eli Lilly and Boehringer Ingelheim.ProStrakan in...
